Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPP-204106N in Advanced Solid Tumors
NCT01711398Phase 2Completed
- Sponsor
- Elro Pharma
- Start
- Jul 2012
- Primary completion
- Sep 2014
- Modality
- RNA Aptamers, Modified Peptides, DNA Aptamers
- Countries
- 2
01
Overview
A Phase 2 trial of N6L in solid tumor (advanced stage), sponsored by Elro Pharma. Started Jul 2012; status: completed.
02
Drugs
N6L
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT01711398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01711398.